{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:57:18Z","timestamp":1792155438111,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002999","name":"Netherlands Ministry of Health Welfare and Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010763","name":"National Health Care Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010763","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcpo.2026.100817","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:12:11Z","timestamp":1791562331000},"page":"100817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Perspectives in the value assessment of comprehensive genomic profiling: A multi-criteria decision analysis in NSCLC among stakeholders"],"prefix":"10.1016","volume":"50","author":[{"given":"L.F.","family":"van Schaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Fern\u00e1ndez","family":"Coves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.E.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"van Til","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Joore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.P.","family":"Ret\u00e8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcpo.2026.100817_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12916-021-02089-z","article-title":"Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer","volume":"19","author":"Zhao","year":"2021","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100817_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-023-02697-7","article-title":"The grand challenge of moving cancer whole-genome sequencing into the clinic","volume":"30","author":"Akhoundova","year":"2024","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.jcpo.2026.100817_bib3","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jval.2024.04.023","article-title":"Assessing the cost-effectiveness of next-generation sequencing as a biomarker testing approach in oncology and policy implications: a literature review","volume":"27","author":"Mirza","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.jcpo.2026.100817_bib4","article-title":"An application of iterative early health economic evaluation: an update on the early cost effectiveness of whole-genome sequencing in advanced non-small-cell lung cancer","author":"Fern\u00e1ndez Coves","year":"2025","journal-title":"Submitt. Value Health"},{"key":"10.1016\/j.jcpo.2026.100817_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103459","article-title":"How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review","volume":"166","author":"Torres","year":"2021","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.jcpo.2026.100817_bib6","unstructured":"Nederland Z.. Standpunt inzake brede moleculaire analyse bij niet-kleincellige longkanker (non-small-cell lung cancer, NSCLC): Zorgverzekeraars Nederland; 2025 [Available from: https:\/\/www.zn.nl\/app\/uploads\/ZN-SWP-2025-002-brede-moleculaire-analyse-NSCLC-1.pdf."},{"key":"10.1016\/j.jcpo.2026.100817_bib7","unstructured":"Zorginstituut Nederland. Stand van Wetenschap en praktijk 2023 https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2023\/04\/11\/beoordeling-swp-20232023 [."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100817_bib8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/s41591-025-03613-x","article-title":"Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial","volume":"31","author":"Tr\u00e9dan","year":"2025","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jcpo.2026.100817_bib9","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/jnci\/djaf015","article-title":"Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementation","volume":"117","author":"Zerdes","year":"2025","journal-title":"JNCI Journal National Cancer Institute"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100817_bib10","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1186\/s12885-024-13167-9","article-title":"Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives","volume":"24","author":"van Schaik","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jcpo.2026.100817_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104441","article-title":"Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review","author":"van Schaik","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.jcpo.2026.100817_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2015.12.003","article-title":"Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force","volume":"19","author":"Thokala","year":"2016","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jcpo.2026.100817_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jval.2015.12.016","article-title":"Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force","volume":"19","author":"Marsh","year":"2016","journal-title":"Value Health"},{"key":"10.1016\/j.jcpo.2026.100817_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2019.112595","article-title":"Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework","volume":"246","author":"Angelis","year":"2020","journal-title":"Social. Sci. & Med."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100817_bib15","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jval.2022.11.007","article-title":"The Use of Multicriteria Decision Analysis to Support Decision Making in Healthcare: An Updated Systematic Literature Review","volume":"26","author":"Gongora-Salazar","year":"2023","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jcpo.2026.100817_bib16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10198-019-01052-3","article-title":"Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art","volume":"20","author":"Oliveira","year":"2019","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.jcpo.2026.100817_bib17","article-title":"Moleculaire diagnostiek in de oncologie","author":"Damen","year":"2021","journal-title":"Zorginstituut Ned. Cochrane"},{"issue":"3","key":"10.1016\/j.jcpo.2026.100817_bib18","first-page":"315","article-title":"Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries","volume":"6","author":"Fontrier","year":"2022","journal-title":"Pharm. - Open."},{"issue":"2","key":"10.1016\/j.jcpo.2026.100817_bib19","first-page":"60","article-title":"Comparative review of selected health technology assessment agencies: Features and insights for health technology assessment development and improvement","volume":"2","author":"Dai","year":"2026","journal-title":"Pharm. Policy"},{"key":"10.1016\/j.jcpo.2026.100817_bib20","article-title":"PFMG2025-integrating genomic medicine into the national healthcare system in France","volume":"50","author":"PFMG2025 contributors","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"issue":"5","key":"10.1016\/j.jcpo.2026.100817_bib21","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41591-022-01777-4","article-title":"A national precision cancer medicine implementation initiative for Norway","volume":"28","author":"Task\u00e9n","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jcpo.2026.100817_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2340\/1651-226X.2024.32661","article-title":"A national precision cancer medicine implementation initiative for Finland","volume":"63","author":"Jalkanen","year":"2024","journal-title":"Acta Oncol."},{"key":"10.1016\/j.jcpo.2026.100817_bib23","author":"NHS","year":"2022","journal-title":"A Strategy Embed. Genom. NHS 5 years"},{"issue":"12","key":"10.1016\/j.jcpo.2026.100817_bib24","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s40273-021-01073-y","article-title":"Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C\/IV Non-squamous Non-small-Cell Lung Cancer","volume":"39","author":"Simons","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100817_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-023-02682-0","article-title":"Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme","volume":"30","author":"Sosinsky","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.jcpo.2026.100817_bib26","unstructured":"Voort Rvd. UMC Utrecht stapt over op een brede moleculaire test voor alle solide tumoren https:\/\/precisieoncologie.nl\/nieuws\/nieuws-over-de-moleculaire-diagnostiek-in-de-oncologische-pathologie\/: Precisie Oncologie Academie; 2024 [Available from: https:\/\/precisieoncologie.nl\/nieuws\/nieuws-over-de-moleculaire-diagnostiek-in-de-oncologische-pathologie\/."},{"issue":"12","key":"10.1016\/j.jcpo.2026.100817_bib27","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1016\/j.jval.2023.09.1725","article-title":"HTA40 Making MCDA'Shiny'With an Adaptive Support Tool for Healthcare Decision-Making: An Application in Broad Molecular Testing With R Shiny","volume":"26","author":"Coves","year":"2023","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jcpo.2026.100817_bib28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.21037\/tlcr-19-403","article-title":"The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility","volume":"9","author":"Liu","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"issue":"11","key":"10.1016\/j.jcpo.2026.100817_bib29","doi-asserted-by":"crossref","first-page":"e1070","DOI":"10.1634\/theoncologist.2018-0572","article-title":"Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer","volume":"24","author":"Wen","year":"2019","journal-title":"oncologist"},{"issue":"1","key":"10.1016\/j.jcpo.2026.100817_bib30","doi-asserted-by":"crossref","DOI":"10.1080\/23311916.2019.1623153","article-title":"Are MCDM methods useful? A critical review of analytic hierarchy process (AHP) and analytic network process (ANP)","volume":"6","author":"Asadabadi","year":"2019","journal-title":"Cogent Eng."},{"key":"10.1016\/j.jcpo.2026.100817_bib31","doi-asserted-by":"crossref","first-page":"33492","DOI":"10.1109\/ACCESS.2022.3161742","article-title":"MCDM and various prioritization methods in AHP for CSS: A comprehensive review","volume":"10","author":"Gyani","year":"2022","journal-title":"IEEE Access."},{"issue":"4","key":"10.1016\/j.jcpo.2026.100817_bib32","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jval.2017.10.001","article-title":"The Use of MCDA in HTA: Great Potential, but More Effort Needed","volume":"21","author":"Marsh","year":"2018","journal-title":"Value Health"}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326001189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538326001189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:21:18Z","timestamp":1792153278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538326001189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":32,"alternative-id":["S2213538326001189"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100817","relation":{},"ISSN":["2213-5383"],"issn-type":[{"value":"2213-5383","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perspectives in the value assessment of comprehensive genomic profiling: A multi-criteria decision analysis in NSCLC among stakeholders","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2026.100817","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100817"}}